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Abstract We investigated the potential of mouse embryonic
stem (ES) cells to differentiate into hepatocytes in vitro.
Differentiating ES cells expressed endodermal-specific genes,
such as K-fetoprotein, transthyretin, K 1-anti-trypsin and
albumin, when cultured without additional growth factors and
late differential markers of hepatic development, such as tyrosine
aminotransferase (TAT) and glucose-6-phosphatase (G6P), when
cultured in the presence of growth factors critical for late
embryonic liver development. Further, induction of TAT and
G6P expression was induced regardless of expression of the
functional SEK1 gene, which is thought to provide a survival
signal for hepatocytes during an early stage of liver morphogen-
esis. The data indicate that the in vitro ES differentiation
system has a potential to generate mature hepatocytes. The
system has also been found useful in analyzing the role of growth
factors and intracellular signaling molecules in hepatic
development. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Embryonic stem (ES) cells are continuously growing stem
cell lines of embryonic origin ¢rst isolated from the inner cell
mass of blastocysts [1,2]. The distinguishing features of ES
cells in mice are their capacity to be inde¢nitely maintained
in an undi¡erentiated state in culture and their potential to
develop into every cell type. ES cells can proliferate in vitro in
an undi¡erentiated state on a feeder layer of mouse embryonic
¢broblast cells (MEF) or in a medium containing leukemia
inhibitory factor (LIF). The most rigorous test of the devel-
opmental potential of mouse ES cells is their ability to con-
tribute to all cell lineages of chimeric animals, including the
germ line [3]. Alternatively, when ES cells are injected into
immunocompromised animals, they form teratomas com-
posed of multiple lineages [2].
In addition to their pluripotent ability to di¡erentiate in
vivo, ES cells can di¡erentiate into multiple cell lineages in
vitro as well. The in vitro di¡erentiation of ES cells is induced
by removing the ES cells from the feeder layer of MEF or by
removing LIF from the culture medium, and then allowing
them to form aggregates in suspension. ES cells aggregate into
structures termed embryoid bodies (EBs), in which all three
germ layers develop and interact with each other. Well-di¡er-
entiated EBs are composed of multiple di¡erentiated cell types
including neuronal, cardiac muscle, hematopoietic, and chon-
drocytic cells. EBs recapitulate many processes that take place
during development [4]. Certain aspects of the kinetics of lin-
eage development observed within EBs show remarkable sim-
ilarities to that observed in the developing embryo [5]. Such
development, however, is spontaneous and in£uenced by ac-
cidental cell-to-cell interactions. In case of hematopoietic com-
mitment, exogenous growth factors e⁄ciently and reproduci-
bly induce lineage-speci¢c precursors [6].
While previous studies have shown that ES cells demon-
strate early endodermal di¡erentiation in vitro [7^10], it re-
mains unclear whether they have the ability to di¡erentiate
into mature endodermal phenotypes such as hepatocytes in
vitro. To this end, we investigated the ability of ES cells to
di¡erentiate into mature hepatocytes in vitro. Further, we
examined the e¡ects of growth factors, cell culture matrix,
and gene modulation on the hepatic maturation in this in
vitro system.
2. Materials and methods
2.1. Cell culture
The ES cell lines R1 (129Sv strain), W9.5 (129Sv), and SEK1 null
(established from W9.5) [11] were maintained undi¡erentiated in gel-
atin-coated dishes in Dulbecco’s modi¢ed Eagle’s medium (Gibco
BRL, Grand Island, NY, USA) containing 15% fetal bovine serum
(Atlanta Biologicals, Norcross, GA, USA), 2 mM L-glutamine, 100
U/ml penicillin, 100 Wg/ml streptomycin, 25 mM HEPES (Gibco
BRL), 300 WM monothioglycerol (Sigma, St. Louis, MO, USA),
and 250 U/ml recombinant mouse LIF (Esgro, Chemicon, Temecula,
CA, USA). To induce di¡erentiation, ES cells were suspended in
Iscove’s modi¢ed Dulbecco’s medium containing 2 mM L-glutamine,
100 U/ml penicillin, 100 Wg/ml streptomycin (Gibco BRL), 20% fetal
bovine serum (Atlanta Biologicals) and 300 WM monothioglycerol
(Sigma). Cells were cultured for 2 days by the hanging drop method
(1U103 ES cells per 30 Wl in each drop) [12]. EBs in hanging drops
were transferred to suspension culture in 100 mm petri dishes and
cultured for an additional 3 days. The resulting EBs were plated
onto six-well tissue culture dishes coated with or without Vitrogen
(collagen type I) (Cohesion, Palo Alto, CA, USA). In some experi-
ments, the growth factors were added into culture medium (100 ng/ml
acidic ¢broblast growth factors (aFGF), 20 ng/ml hepatocyte growth
factor (HGF), 10 ng/ml oncostatin M (OSM), with 1037 M dexa-
methasone (Dex; Sigma), and ITS (5 mg/ml insulin, 5 mg/ml trans-
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ferrin, 5 Wg/ml selenious acid, Collaborative Biomedical Products,
Benford, MA, USA)).
2.2. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted by using an RNA aqueous kit (Ambion,
Austin, TX, USA). cDNA was synthesized from 2 Wg total RNA by
using SuperScript II ¢rst-strand synthesis system with oligo (dT) (Gib-
co BRL). PCR was performed by using Taq DNA polymerase (Ep-
pendorf, Westbury, NY, USA) (94‡C, 1 min; speci¢c annealing tem-
perature below, 1 min; 72‡C, 1 min). Primers were synthesized for the
following mouse genes (oligonucleotide sequences are given in brack-
ets in the order of anti-sense, sense primer followed by the annealing
temperature, cycles used for PCR and length of the ampli¢ed frag-
ment): transthyretin (TTR) (5P-CTCACCACAGATGAGAAG, 5P-
GGCTGAGTCTCTCAATTC; 55‡C; 25 cycles; 225 bp), K-fetopro-
tein (AFP) (5P-TCGTATTCCAACAGGAGG, 5P-AGGCTTTTGCT-
TCACCAG; 55‡C; 25 cycles; 173 bp), K 1-anti-trypsin (AAT) (5P-
AATGGAAGAAGCCATTCGAT, 5P-AAGACTGTAGCTGCTGC-
AGC; 55‡C; 30 cycles; 484 bp), albumin (ALB) (5P-GCTACGGCA-
CAGTGCTTG, 5P-CAGGATTGCAGACAGATAGTC; 55‡C; 25
cycles; 260 bp), glucose-6-phosphatase (G6P) (5P-CAGGACTGGTT-
CATCCTT, 5P-GTTGCTGTAGTAGTCGGT; 55‡C; 30 cycles; 210
bp), tyrosine aminotransferase (TAT) (5P-ACCTTCAATCCCATCC-
GA, 5P-TCCCGACTGGATAGGTAG; 50‡C; 30 cycles; 206 bp),
L-actin (5P-TTCCTTCTTGGGTATGGAAT, 5P-GAGCAATGATC-
TTGATCTTC; 55‡C; 20 cycles; 200 bp), SEK1 (5P-TGTATGGA-
GCTCATGTCTACC, 5P-GTCTATTCTTTCAGGTGCCA; 50‡C;
30 cycles; 300 bp).
For each gene, the DNA primers were originated from di¡erent
exons to ensure that the PCR product represents the speci¢c
mRNA species and not genomic DNA. Relative quantitation of
ALB gene was performed by ABIPRISM5700 sequence detection sys-
tem and SYBR green PCR master mix (PE Biosystems, Foster City,
CA, USA). L-Actin was used as the endogenous control.
2.3. JNK activity
JNK activity in cell lysates was measured by immunocomplex pro-
tein kinase assays using the substrate glutathione S-transferase (GST)-
c-Jun (1^79) fusion protein [13,14]. Cell lysates were incubated 30 min
with GST-c-Jun (1^79) fusion proteins immobilized on glutathione^
Sepharose beads to precipitate JNKs. These beads were resuspended
in 50 Wl of kinase bu¡er (20 mM HEPES, 20 mM L-glycerophosphate,
1 mM dithiothreitol, 50 WM Na3VO4, and 10 mM MgCl2, 10 WCi
[Q-32P]ATP). The kinase reaction was performed at 30‡C for 20 min,
and stopped by adding SDS sample bu¡er. The samples were resolved
in a SDS gel. The gel was stained with Coomassie brilliant blue so-
lution for 5 min and destained, then air dried. Phosphorylated GST-c-
Jun was visualized by autoradiography.
3. Results
3.1. In vitro ES di¡erentiation to hepatic lineage
To assess the level of endodermal and hepatic di¡erentia-
tion, we examined the mRNA expression of endodermal- and
liver-speci¢c genes. TTR and AAT represent endodermal or
yolk-sac-like di¡erentiation and are expressed throughout liv-
er maturation [15,16]. AFP is a marker of the endodermal
di¡erentiation as well as an early fetal hepatic marker, and
its expression decreases as the liver develops into adult phe-
notype. Expression of ALB, the most abundant protein syn-
thesized by mature hepatocytes, starts in early fetal hepato-
cytes (E12) and reaches the maximal level in adult hepatocytes
[17]. Although ALB is known to be a hepatocyte di¡erentia-
tion marker, it is also expressed weakly in yolk sac. At a late
gestational or perinatal stage, G6P is predominantly expressed
in the liver [18]. TAT represents an excellent enzymatic
marker for peri- or postnatal hepatocyte-speci¢c di¡erentia-
tion. These enzymes are not synthesized in signi¢cant quanti-
ties prior to birth but are rapidly activated early in the neo-
natal developmental period [19]. Since hormone-regulated
TAT activity is strictly limited to the parenchymal cells of
the adult liver, it has been used extensively for monitoring
cellular di¡erentiation in experimental models for liver devel-
opment/maturation in vitro [20,21].
Undi¡erentiated ES cells did not express these endodermal
or hepatocyte lineage genes. Fig. 1 depicts the in vitro ES
di¡erentiation procedure used in this study. Fig. 2 illustrates
the pattern of endodermal-speci¢c gene expression in di¡er-
entiating EBs without additional growth factors. TTR was
expressed within 6 days after removal of the LIF. AFP and
AAT were expressed within day 9. ALB mRNA expression
¢rst appeared within day 12. Late di¡erential markers of hep-
atocyte, TAT and G6P were not detectable throughout the
time course (up to day 18). These data indicate that ES cells
spontaneously di¡erentiate toward hepatic or yolk sac lineage
cells, but they do not di¡erentiate into mature hepatocytes.
3.2. Induced hepatic maturation in vitro
During embryonic development of mice, the initial event of
liver ontogeny occurs on embryonic day 9 (E9). In this early
stage, FGFs, derived from adjacent cardiac mesoderm, com-
mit the foregut endoderm to forming the liver primodium [22].
Over the next 2 days, the liver bud proliferates and migrates
into surrounding septum transversum, which consists of loose
connective tissue containing collagen. Hepatic precursors are
in direct contact with connective tissue matrix [23]. During
and after the mid-stage of hepatogenesis, surrounding mesen-
chymal cells secrete HGF and support fetal hepatocytes. In-
Fig. 1. In vitro hepatic lineage di¡erentiation of ES cells. The in vitro di¡erentiation protocol used in the study is illustrated. In some experi-
ments, growth factors were added based on previous studies in embryonic liver development. Acidic FGF (100 ng/ml) was added between days
9 and 12 as an early stage factor for hepatic maturation. HGF (20 ng/ml) was added between days 12 and 18 as a mid-stage factor. OSM
(10 ng/ml), Dex (1037 M), and ITS mixture (5 mg/ml insulin, 5 mg/ml transferrin, 5 Wg/ml selenious acid) were added as late stage factors be-
tween days 15 and 18.
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deed, in mice genetically lacking HGF, the embryonic liver is
reduced in size and shows extensive loss of parenchymal cells
[24,25]. From E12 through E16, the fetal liver becomes the
major site for hematopoiesis [26]. During this late stage, hem-
atopoietic cells produce OSM that induces maturation of mur-
ine fetal hepatocytes [27].
Based on these previous reports for embryonic liver devel-
opment, we applied growth factors and cell culture matrix to
induce hepatic maturation of EBs in vitro (Fig. 1). Initially we
attached EBs on collagen-coated culture plates at day 5 in
vitro di¡erentiation. As an early stage factor potentially in-
ducing hepatic di¡erentiation, aFGF was added from day 9 to
day 12. From day 12 to day 18, HGF was added as a mid-
stage factor. OSM, Dex and a mixture of insulin, transferrin
and selenious acid (ITS) were added as late stage factors from
day 15 to day 18. We analyzed the patterns of hepatic lineage
gene expression at day 18. As shown in Fig. 3, a combination
of these growth factors enhanced the expression of ALB
mRNA, which is an indicator of hepatocyte maturation.
The expression of ALB was increased 9.5-fold and 7.4-fold
(real-time PCR) by the growth factors on collagen-uncoated
culture and collagen-coated culture, respectively. Moreover,
G6P and TAT genes, indicators of hepatocyte maturation,
were now expressed in EBs in the presence of the growth
factors. It appeared that collagen coating further enhanced
the expression of G6P and TAT.
We then examined the e¡ects of growth factors at individ-
ual stages on hepatic development using EBs plated on colla-
gen-coated dishes. As demonstrated in Fig. 4a, the mid-stage
factor (HGF) or late stage factors (OSM, Dex, ITS) were
critical for G6P expression. The late stage factors exclusively
enhanced TAT gene expression. Although Dex, by itself,
slightly induced TAT expression, the mixture of the late stage
factors mostly enhanced the TAT expression (Fig. 4b).
3.3. Maturation of SEK1 null ES cells into hepatic lineage in
vitro
SEK1 (also known as MKK4 and JNKK) is a member of
the mitogen-activated protein kinase activator family [28,29].
SEK1 de¢ciency leads to an embryonic lethality between
E10.5 and E12.5 and is associated with abnormal liver devel-
Fig. 2. Expression of endodermal and hepatic di¡erentiation marker
genes in di¡erentiating ES cells. ES cells were cultured under the
protocol shown in Fig. 1 without using collagen-coated dish nor ad-
ditional growth factors for hepatic maturation. Cells were harvested
at the indicated time (days). mRNA expression of TTR, AFP,
AAT, ALB, G6P, TAT and L-actin was examined by RT-PCR as
described in Section 2. Molecular size marker for DNA (M), fetal
liver at embryonic day 12 (FL), adult liver at 3 weeks old (AL). Re-
sults shown here and below are representative of three to ¢ve inde-
pendent experiments.
Fig. 3. E¡ects of collagen-coated dish and addition of growth fac-
tors on expression of late hepatic di¡erentiation markers. ES cells
were cultured under the protocol shown in Fig. 1 with or without
the use of a collagen-coated dish, in the absence or presence of
growth factors (GFs) for hepatic maturation. Cells were harvested
at day 18, and mRNA expression of ALB, G6P, TAT and L-actin
was examined by RT-PCR as described in Section 2. Fetal liver at
embryonic day 12 (FL), adult liver at 3 weeks old (AL).
Fig. 4. E¡ects of early, mid- and late stage factors on expression of
late hepatic di¡erentiation markers. ES cells were cultured under the
protocol shown in Fig. 1. a: No growth factor (none), early stage
factor alone (early), mid-stage factor alone (mid), late stage factors
alone (late), mid- and late stage factors (mid/late), or early, mid-
and late stage factors (early/mid/late) were added as growth factors
for hepatic maturation. b: No growth factor (none), OSM, Dex and
ITS mixture (OSM/Dex/ITS), OSM, Dex, or ITS mixture (ITS)
were added as late growth factors for hepatic maturation. No early
or mid factors were added. Cells were harvested at day 18, and
mRNA expression of G6P, TAT, and L-actin was examined by RT-
PCR as described in Section 2.
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opment [30]. SEK1 null fetal mice show that the visceral en-
doderm normally develops into primordial liver, but paren-
chymal hepatocytes undergo massive apoptosis. This phenom-
enon indicates that the SEK1 signaling pathway is exclusively
required after a certain period of early hepatogenesis [31,11].
Because of its embryonic lethality, it is hard to further assess
the role of SEK1 in the late stage hepatogenesis in vitro.
Using the in vitro ES cell di¡erentiation system described
above, we investigated the potential of SEK1 null ES cells to
di¡erentiate into mature hepatocytes. Fig. 5a showed the ex-
pression of SEK1 mRNA in di¡erentiated EBs (day 18). We
con¢rmed that SEK1 mRNA was not detected in SEK1 null
EBs. The expression of TAT and G6P mRNA was induced in
SEK1 null EBs by late stage growth factors as well as in
control wild type EBs (Fig. 5b). The late stage growth factors
induced JNK activity, a downstream kinase of SEK1, in wild
type EBs but not in SEK1 null EBs (Fig. 5c). These data
indicated that the SEK1 signaling pathway is not indispensa-
ble in late stage maturation of hepatocytes.
4. Discussion
The ability of ES cells to develop into a wide range of cell
types in vitro has drawn much attention to ES cells as a basic
research tool and as a novel source for potential cell therapy
[32], particularly after human ES cells were established [33,34].
Despite intensive studies of in vitro di¡erentiation of ES cells
in other lineages, hepatic di¡erentiation of ES cells has not yet
been reported with the exception of early to mid-endodermal
di¡erentiation of ES cells up to the stage of ALB production,
which, by itself, could not distinguish hepatic di¡erentiation
from yolk sac lineage di¡erentiation. Here we demonstrated
that ES cell di¡erentiation in vitro would not surpass this
stage spontaneously without additional growth factors. How-
ever, addition of hepatocyte maturation factors did induce
expression of mature hepatocyte-speci¢c genes in di¡erentiat-
ing ES cells, suggesting that ES cells have a potential to be-
come mature hepatocytes in vitro. This ¢nding indicates that
it is possible to generate functional hepatocytes in vitro from
di¡erentiating ES cells. Since cell replacement therapy using
primary hepatocytes has been shown to be e¡ective in animal
models of hepatic failure and liver-based metabolic diseases
[35^38], an alternative source of functional hepatocytes would
be bene¢cial.
Since di¡erentiating EBs recapitulate many processes taking
place in normal embryonic development, in vitro ES di¡er-
entiation serves as an excellent system to study lineage-speci¢c
development. In the current study, endodermal and hepato-
cyte lineage genes were sequentially expressed in a fashion
similar to that found in the normal embryo. In addition,
late hepatocyte maturation factors, including OSM, indeed
induced expression of mature hepatocyte-speci¢c genes in dif-
ferentiating ES cells. These data indicate that the in vitro ES
di¡erentiation system is a useful tool to study hepatic develop-
ment.
Another advantage of this in vitro ES-to-hepatocyte di¡er-
entiation system is the ability to rapidly determine the role of
a speci¢c gene in speci¢c tissues. In contrast, most studies in
gene function require generation of transgenic and/or gene
knockout animals, which are considered to be long-term as-
says. We previously demonstrated the usefulness of this in
vitro ES di¡erentiation system combined with targeted gene
disruption to de¢ne complex regulatory events in a cardiac
disease model [39]. In particular, this in vitro system is useful
when targeting of a gene leads to an early embryonic death as
seen with the SEK1 knockout mice. It has been suggested that
the SEK1 signaling cascade is related with cell survival under
a variety of cellular stresses or under stimulation with growth
factors [29,40]. SEK1 appears to induce anti-apoptotic genes
in developing hepatocytes and/or directly a¡ect signaling
pathways required for cell survival [31,11]. In these in vivo
studies, it was shown that hepatic di¡erentiation itself was not
disturbed by SEK1 deletion, at least to the stage of ALB
Fig. 5. E¡ects of SEK1 knockout on expression of late hepatic dif-
ferentiation markers. SEK1 null ES cells (SEK13/3) and their pa-
rental ES cells (SEK1+/+) were cultured under the protocol shown
in Fig. 1. a: SEK1 expression. Cells were harvested at day 18, and
expression of SEK1 mRNA was examined using RT-PCR as de-
scribed in Section 2. b: Induced expression of G6P and TAT. No
growth factor (none), late stage factors alone (late), mid- and late
stage factors (mid/late), or early, mid- and late stage factors (early/
mid/late) were added as growth factors for hepatic maturation. Cells
were harvested at day 18, and mRNA expression of G6P, TAT,
and L-actin was examined by RT-PCR as described in Section 2. c:
JNK activity. Late stage factors were added into di¡erentiating ES
cells at day 15. Cells were harvested at the indicated time after addi-
tion of the factors (0, 15 or 30 min later). As a control, cells were
irradiated by ultra-violet for 15 min. JNK activity in the cell lysates
was measured as described in Section 2.
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expression. By using the in vitro ES di¡erentiation system, we
demonstrated that SEK1 is not indispensable for hepatic mat-
uration to a later stage of liver development.
In summary, we have demonstrated the potential of mouse
ES cells to di¡erentiate into mature hepatocytes in vitro. Fur-
ther, we demonstrated the ES di¡erentiation system in vitro is
a useful model for analyzing the role of speci¢c growth factors
and intracellular signaling molecules in hepatic development.
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